Prot #16244: A Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multicenter, Event-Driven Phase III Study to Investigate the Efficacy and Safety of Finerenone, in Addition to Standard of Care, on the Progression of Kidney Disease in Subjects